Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claim about OPZELURA’s labeled risks (serious infections including sometimes fatal; mortality; malignancy; MACE; thrombosis) and associated precautions is supported by the provided FDA prescribing information sections 5.1–5.5. No direct contradictions or unsupported safety claims were identified based on the supplied label excerpts.
Category Scores
Accurate Statements
OPZELURA (ruxolitinib) is associated with serious infections (including sometimes fatal), with precautions to avoid use in patients with active serious infection and to interrupt if serious infection/opportunistic infection/sepsis occurs.
Supported by Warnings and Precautions 5.1 (Serious Infections).
OPZELURA has increased mortality risk as described in labeling, with advice to consider benefits and risks prior to initiating or continuing therapy.
Supported by Warnings and Precautions 5.2 (Mortality).
OPZELURA is associated with malignancy risk (including lymphomas), with additional emphasis on risk considerations (e.g., smoking) and other malignancy-related warnings.
Supported by Warnings and Precautions 5.3 (Malignancy and Lymphoproliferative Disorders).
OPZELURA is associated with MACE risk, with guidance to consider benefits/risks and to discontinue after MI or stroke.
Supported by Warnings and Precautions 5.4 (Major Adverse Cardiovascular Events (MACE)).
OPZELURA is associated with thrombosis risk (including DVT, PE, and arterial thrombosis), with guidance to avoid patients at increased risk and to discontinue and evaluate if symptoms occur.
Supported by Warnings and Precautions 5.5 (Thrombosis).
Unsupported Statements
Contradictions
Important Omissions
No omission assessed for the specific evaluated claim; however, the evaluated statement is somewhat general (e.g., does not explicitly mention TB, viral reactivation/herpes zoster, or hepatitis B/C initiation recommendation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim accurately reflects labeled boxed-warning-style safety risks and the existence of corresponding precautions; it does not add extraneous or inconsistent safety assertions based on the supplied label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The claim is broad and does not enumerate some specific labeled infection subtypes/precautions (e.g., TB, herpes zoster reactivation guidance, hepatitis B/C initiation not recommended).
Suggested Improvement
Optionally specify that the label includes TB/viral reactivation and hepatitis B/C initiation guidance within the serious infection precautions, if the goal is to mirror the label more closely.